mTOR Is a Promising Therapeutic Target Both in Cisplatin-Sensitive and Cisplatin-Resistant Clear Cell Carcinoma of the Ovary
Seiji Mabuchi(The University of Osaka), Tadashi Kimura(Sakai Municipal Hospital), Masahiko Tsujimoto(Osaka Police Hospital), Deborah A. Altomare(University of Central Florida), Mareo Yamoto(Fox Chase Cancer Center), Masami Hayashi(Yamagata University), Chiaki Kawase(Yamagata University), Andres J. Klein–Szanto, Ken‐ichirou Morishige(Gifu University), Russell J. Schilder(Yamagata University), Kenjiro Sawada(Gynecologic Oncology Group), Masahide Ohmichi(Osaka University of Pharmaceutical Sciences), Joseph R. Testa(Fox Chase Cancer Center)
Cited by 155
Related Papers
Integrated genomic analyses of ovarian carcinoma
|Nature|2011|8.2k
Skin Tumor-Promoting Activity of Benzoyl Peroxide, a Widely Used Free Radical-Generating Compound
|Science|1981|507
Genetic Dissection of the Oncogenic mTOR Pathway Reveals Druggable Addiction to Translational Control via 4EBP-eIF4E
|Cancer Cell|2010|463
Estrogen Induces the Akt-dependent Activation of Endothelial Nitric-oxide Synthase in Vascular Endothelial Cells
|Journal of Biological Chemistry|2001|387
High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas.
|Proceedings of the National Academy of Sciences|1995|365